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Abstract
Background: Dendritic cells are professional antigen-presenting cells that play an essential role in the initiation and
modulation of T cell responses. They have been studied widely for their potential clinical applications, but for
clinical use to be successful, alternatives to xenogeneic substances like fetal bovine serum (FBS) in cell culture need
to be found. Protocols for the generation of dendritic cells ex vivo from monocytes are well established for several
species, including horses. Currently, the gold standard protocol for generating dendritic cells from monocytes
across various species relies upon a combination of GM-CSF and IL-4 added to cell culture medium which is
supplemented with FBS. The aim of this study was to substitute FBS with heterologous horse serum. For this
purpose, equine monocyte-derived dendritic cells (eqMoDC) were generated in the presence of horse serum or FBS
and analysed for the effect on morphology, phenotype and immunological properties. Changes in the expression
of phenotypic markers (CD14, CD86, CD206) were assessed during dendritic cell maturation by flow cytometry. To
obtain a more complete picture of the eqMoDC differentiation and assess possible differences between FBS- and
horse serum-driven cultures, a transcriptomic microarray analysis was performed. Lastly, immature eqMoDC were
primed with a primary antigen (ovalbumin) or a recall antigen (tetanus toxoid) and, after maturation, were co-
cultured with freshly isolated autologous CD5+ T lymphocytes to assess their T cell stimulatory capacity.
Results: The microarray analysis demonstrated that eqMoDC generated with horse serum were indistinguishable
from those generated with FBS. However, eqMoDC incubated with horse serum-supplemented medium exhibited a
more characteristic dendritic cell morphology during differentiation from monocytes. A significant increase in cell
viability was also observed in eqMoDC cultured with horse serum. Furthermore, eqMoDC generated in the
presence of horse serum were found to be superior in their functional T lymphocyte priming capacity and to elicit
significantly less non-specific proliferation.
Conclusions: EqMoDC generated with horse serum-supplemented medium showed improved morphological
characteristics, higher cell viability and exhibited a more robust performance in the functional T cell assays.
Therefore, horse serum was found to be superior to FBS for generating equine monocyte-derived dendritic cells.
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Background
Dendritic cells are antigen-presenting cells specialized in
uptake and presentation of antigens to T cells [1]. They
are the only antigen-presenting cells capable of inducing
primary immune responses in naïve T cells and are thus
pivotal for the development of T cell responses [2, 3].
The function of dendritic cells is reflected in a number
of specific properties. Their distinct shape with many
cellular processes offers a large surface area for antigen
recognition and uptake [4]. Furthermore, the high sur-
face expression of MHC class II in connection with high
levels of costimulatory molecules allows for optimal
stimulation of T cells. Initially, studies using dendritic
cells have been hindered by difficulties in obtaining suffi-
cient numbers of these cells, as their frequency is very
low (<1%). The discovery that granulocyte-macrophage
colony stimulating factor (GM-CSF) was the key cyto-
kine needed to differentiate viable dendritic cells from
murine blood [5] allowed the development of standard-
ized methods to generate large numbers of dendritic
cells ex vivo from hematopoietic progenitors. In humans,
dendritic cells can be generated from peripheral blood
CD14+ monocytes by using GM-CSF and Interleukin-4
(IL-4) [6, 7]. Due to the higher frequency of CD14+ cells,
this method has been widely used to generate dendritic
cells for experimental purposes in the human field and
for immunotherapy. Monocyte-derived dendritic cells
(MoDC) were shown to be homogeneous and could be
fully matured using autologous monocyte-conditioned
medium [8, 9] or, alternatively, through a cocktail of in-
flammatory cytokines, namely IL-1β, Tumor necrosis
factor-α (TNF-α), IL-6 and Prostaglandin E2 (PGE2)
[10]. The generation of MoDC has been described in a
number of domestic animal species such as cattle [11],
pigs [12], sheep [13] and horses [14–17].
Fetal bovine serum (FBS) represents an important
source of nutrients for in vitro cell growth, metabolism
and proliferation [18] and is widely used in cell culture
media. Prior to the emergence of variant Creutzfeldt-
Jakob disease as a result of the bovine spongiform en-
cephalitis (BSE) crisis at the end of last century, FBS was
considered reasonably safe for humans. In animals how-
ever, the safety of FBS was always more questionable
with more animal diseases potentially being transmis-
sible between species. The main advantage in using
serum from unborn animals consists in the absence of
interfering substances like inflammatory molecules, hor-
mones or exogenous antigens, including feed-derived
components. However, FBS batches are known to be
heterogeneous in their performance and need to be
batch-tested. Moreover, diluted and altered FBS has been
sold recently in Europe, underlining the challenges to
FBS selection [19]. Accordingly, FBS production is in-
creasingly subject to regulations and restrictions, not least
to protect animals under the 3R guidelines and reduce un-
necessary pain, suffering, distress or lasting harm.
In recent years, the ex vivo generation of dendritic cells
for the induction of anti-tumor responses has been a focus
point for cancer immunotherapy research [20–23]. When
generating dendritic cells for clinical applications, such as
tumor vaccines, reproducibility and safety are of para-
mount importance. The use of FBS as a poorly defined
cocktail of proteases and other active substances has
always been less than ideal, and for both humans and
animal species, the use of xenogeneic reagents needs to be
avoided.
The utility of autologous serum or serum free media for
the generation of MoDC has been questioned [24–26]. In
horses, the use of homologous serum for cell culture has
been described widely in systems other than DC gener-
ation or maintenance. Hamza et al. [27] used autologous
serum in cell culture for functional assays involving
equine peripheral blood mononuclear cells (PBMC). The
use of horse serum for culture of primary equine bron-
chial fibroblasts [28] has also been described.
In the present study we examined the morphology, via-
bility, phenotype and functional properties of eqMoDC
generated under different serum conditions. For this
purpose, three FBS batches from two different manufac-
turers were compared to horse serum produced in one of
our laboratories. The data demonstrate that eqMoDC
generated in the presence of heterologous horse serum
perform equally well or better than dendritic cells gener-
ated with FBS.
Methods
Horses and blood samples
Blood samples were collected from the jugular vein of
six healthy horses (4 geldings, 2 mares) using Sodium-
Heparin containing vacutainers (Vacuette®; Greiner,
St.Gallen, Switzerland). The horses were of diverse
breeds (Warmblood, Freiberger, Icelandic horse) and
spanned a large age range (4–25 years, mean age = 12.7
years). They had been vaccinated yearly against equine
influenza and tetanus, and dewormed regularly. The
horses belonged to the Swiss Institute of Equine Medi-
cine, Vetsuisse Faculty, University of Bern.
Horse and fetal bovine sera
For preparation of horse serum (HS), blood was collected
from a healthy horse into Serum Clot Activator containing
vacutainers (Vacuette®; Greiner, St.Gallen, Switzerland).
HS was separated by leaving the blood to clot for 2 h
followed by centrifugation at 2684×g (Rotanta 46 RSC
centrifuge, Hettich AG, Bäch, Switzerland) for 10 min at 4
°C and inactivation for 30 min at 56 °C in a water bath.
Serum was then stored at -20 °C until used.
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Three commercially available batches of fetal bovine
serum were used: FBS (A15-101), Lot A10106-1060 (PAA
Pasching, Austria); FBS (S0113), Lot 1107A (Biochrom
GmbH, Berlin Germany); FBS Superior (S0613), Lot
0503B, (Biochrom).
In vitro generation of eqMoDC
PBMC were isolated by two sequential Ficoll density gra-
dient centrifugations, using Biocoll 1.090 g/ml and 1.077
g/ml (Biochrom) as described by Mauel et al. [14]. The
PBMC-containing fraction was then washed twice in
PBS and re-suspended in PBS supplemented with 2 mM
EDTA and 0.5% of FBS or HS. Monocytes were isolated
by magnetic separation (MACS technology, Miltenyi
Biotec GmbH, Bergisch-Gladbach, Germany) according
to the manufacturer’s standard protocols, using a mono-
clonal anti-equine CD14 antibody (clone 105) [29].
Briefly, PBMC were first incubated with anti-CD14 and,
after a washing step, with secondary goat anti-mouse
micro beads. The cells were then separated on a LS col-
umn (Miltenyi Biotec GmbH). 2 × 106 monocytes were
incubated in a 12-well tissue culture plate (Falcon, BD
Biosciences, San Jose CA, USA) in 2 ml RPMI 1640
medium with HEPES and L-glutamine (Gibco, Life
Technologies Ltd, Paisley UK) supplemented with 1%
penicillin and streptomycin (Gibco), 1% MEM vitamins,
1% Na pyruvate, 1% Non-essential amino acids (all Bio-
chrom) and either 10% FBS (A15-101), FBS (S0113), FBS
(S0613) or 5% HS.
Endotoxin contamination was assessed in all serum-
supplemented media using a qualitative in vitro end-point
endotoxin assay (ToxinSensor™, GenScript, Piscataway,
NJ, USA). Lipopolysaccharide (LPS) levels were below
0.06 I.U./ml in all media. Differentiation into eqMoDC
was induced by addition of 25 ng/ml recombinant (r.)
equine GM-CSF and 10 ng/ml (r.) equine IL-4 (both King-
fisher Biotech Inc., St. Paul MN, USA) and cells were cul-
tured for 3 days. Cells were monitored daily by light
microscopy for changes in morphology.
Viability assessment
Viability of three day old immature eqMoDC was
assessed using the Alexa Fluor 488 annexin V/Dead Cell
Apoptosis Kit for Flow Cytometry (Invitrogen Life Tech-
nologies, Paisley, UK) according to the protocol provided
by the manufacturer. Briefly, cells were harvested from
the cell culture plates, washed and an aliquot of cells
was suspended in 0.4% Trypan Blue for counting using a
hemocytometer (Neubauer). The cells were resuspended
in annexin-binding buffer, incubated with 5 μl AF488
annexin V and 1 μl of 100 μg/ml propidium iodide for
15 minutes at room temperature, then analysed immedi-
ately by flow cytometry.
Analysis of eqMoDC phenotype by flow cytometry
MoDC phenotypes were assessed by surface marker
expression analysis using the following monoclonal anti-
bodies: anti-equine CD14 mAb (clone 105) [29], anti-
human CD206 clone 3.29B1.10 (Beckman Coulter, High
Wycombe, UK) and anti-human CD86 clone IT2.2
(Becton Dickinson, Oxford, UK). Unlabelled antibodies
were labelled using anti-mouse IgG1 zenon Kits (Invitrogen
Life Technologies). Appropriate isotype controls were used.
Analysis of cells was performed using a BD LSRII Flow
Cytometer (BD Biosciences) and FlowJo software 6 (Tree
Star Inc. Ashland OR, USA).
Transcriptome analysis of eqMoDC populations
RNA was extracted from cell pellets of 1 × 106 cells using
the RNAqueous micro Kit (Life Technologies, Qiagen,
Crawley, UK) and stored at -80 °C. RNA quality was
assessed with the RNA 6000 Pico Labchip kit on the Agi-
lent 2100 Bioanalyzer (Agilent Technologies, Berkshire,
United Kingdom). The Ovation PicoSL WTA System v2 kit
(NuGEN, Leek, The Netherlands) was used to amplify
cDNA from 50 ng total RNA. The MinElute Reaction
Cleanup Kit (Qiagen) option was used to purify cDNA, and
1 μg was then labelled using a one-color DNA labelling kit
(NimbleGen, Madison, USA). For each sample, 4 μg la-
belled cDNA was hybridised to the NimbleGen 12 × 135 K
custom equine arrays (Roche, Madison, USA). Three bio-
logical repeats were analysed for each data set. Hybridised
arrays were scanned at 2 μm resolution with the Agilent
High-resolution C Microarray Scanner (Agilent, Woking-
ham, UK). Microarray images were processed using DEVA
v1.2.1 software (Roche, Madison, USA) to obtain a report
containing the signal intensity values corresponding to each
probe. The raw data was pre-processed using the DEVA
v1.2.1 software by log2 transformation followed by RMA
normalisation and summarisation to yield a signal intensity
value for each probe set. The data set was then filtered by
variance and Principal Component Analysis (PCA) was per-
formed using Qlucore v2.0 software (Qlucore, Lund,
Sweden). Variance levels were set using the δ/δmax method.
EqMoDC maturation and functional T cell stimulation
assays
For antigen-presentation assays, immature eqMoDC were
re-suspended at 2×105 cells per 150ul of RPMI 1640
complete medium containing FBS or HS and incubated for
90 min at 37 °C either with 20 μg/ml tetanus toxoid
(Schweizerisches Serum und Impfinstitut Bern,
Switzerland) as a recall antigen, or 20 μg/ml of the primary
antigen ovalbumin (OVA, kindly provided by the Swiss
Institute for Allergy and Asthma Research, University of
Zürich, Davos Switzerland), or with medium alone as a
control. After antigen uptake, eqMoDC were washed and
cultured in a 96-well round bottom tissue culture plate
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(Sarstedt, Nümbrecht, Germany) at 2×104 eqMoDC per
well in quadruplicates.
For maturation, antigen-primed eqMoDC were exposed
overnight to a maturation cocktail comprising 1 μg/ml
LPS (Sigma-Aldrich St. Louis MO, USA), 1 μg/ml PGE2
(Enzo Life Sciences, Exeter, UK), 20 ng/ml equine TNF-α,
10 ng/ml equine IL-1β, 20 ng/ml equine IL-6 and 100 ng/
ml equine IFN-γ (all R&D Systems, Abingdon, UK)
according to Moyo et al. [17].
Fresh CD5+ T lymphocytes were enriched by positive se-
lection using MACS technology as above-mentioned,
employing an anti-equine CD5 mAb (clone CVS5, Abd
Serotec, Kidlington UK) and re-suspended in RPMI 1640
medium containing FBS or HS, respectively. Purity of CD5
+ lymphocytes after bead selection was assessed by flow cy-
tometry and was shown to be > 94%. 105 autologous CD5+
T lymphocytes were added to the MoDC in the 96-well
plate and co-cultured for 5 days at 37 °C/5% CO2. 5 μCi/
well [3H] thymidine (Perkin Elmer, Waltham MA, USA)
was added for the last 18 h of culture. DNA was then
harvested onto a glass fibre filter plate and thymidine
incorporation was measured on a scintillation counter
(Inotech, LabLogic Systems Inc., Brandon FL, USA).
A mixed leukocyte reaction (MLR) was performed in
addition to the autologous co-cultures by incubating matured
eqMoDC with CD5+ T lymphocytes from another horse.
Statistical analysis
Statistical analyses were carried out using the software
program NCSS 8 (NCSS, Kaysville, Utah 84037, USA).
Descriptive statistics showed that the data were not nor-
mally distributed. Therefore, non-parametric tests were
used. The proportion of non-viable immature MoDC
(Fig. 2), as well as the yield of immature eqMoDC
(Table 1), was compared between the four serum culture
conditions by using a non-parametric paired sample
Wilcoxon (signed rank) test. The same test was used to
determine differences in surface marker expression be-
tween eqMoDC before and after maturation (Fig. 3). A
one-way ANOVA with Tukey-Kramer test for multiple
comparisons was used to assess significant differences
between the individual serum conditions within one
maturation state (Fig. 3).
Non-parametric paired sample Wilcoxon (signed rank)
test was again used to assess differences in serum condi-
tions with regard to induction of T cell proliferation by
antigen-primed MoDC (Figs. 5 and 6). Overall, p-values
≤ 0.05 were considered significant.
Results
Morphology of differentiating eqMoDC differs between
cells generated in the presence of HS or FBS
During differentiation from monocytes, MoDC undergo a
distinct change in morphology. Equine CD14+ monocytes
presented themselves as round cells that adhere quickly to
cell culture plates. After 24 hours of stimulation, a forma-
tion of tight cell clusters could be seen. These became lar-
ger and denser as differentiation progressed (Fig. 1). Also,
cellular dendrites could be seen by that time protruding
from the clusters. After another 24 to 48 hours, the differ-
entiated eqMoDC detached from the clusters and could be
identified as large, heterogeneously formed cells with dis-
tinctive long dendrites. Marked differences in the morph-
ology of the differentiating eqMoDC between serum
conditions were observed. Cluster formation seemed to be
impaired in all cells cultured with FBS in comparison to
cells cultured in the presence of HS, where the vast major-
ity of cells had formed into very distinct dense clusters
(Fig. 1a). Cluster formation was less clear with both FBS
from Biochrom (Fig. 1b, c) and almost non-observable with
FBS batch A15-101 (Fig. 1d). Also, in the clusters that were
present in FBS treated cells, fewer dendrites could be seen
in comparison to HS. With FBS S0113 in particular, several
long spindly cells were seen that could be an indicator of
excess IL-4 in the culture [7]. However, identical concentra-
tions of IL-4 were used for all serum conditions. When
looking at individual cells in the 40× magnification (Fig. 1,
small inlaid pictures), no significant differences could be de-
termined between serum conditions. An intriguing finding
with FBS A15-101 were large round objects enclosed by a
clearly visible membrane, as indicated by the arrow in
Fig. 1d.
Immature eqMoDC generated in the presence of HS
exhibit a higher viability
It is essential for dendritic cells generated in vitro to
maintain viability and thus be able to perform their
functional tasks in downstream assays without becoming
saturated with apoptotic material. Table 1 exhibits rela-
tive cell counts of differentiated eqMoDC following 3
days of incubation, starting with an identical number of
Table 1 Cell counts of immature eqMoDC generated after 3
days in vitro
Horse HS FBS (A15-101) FBS (S0113) FBS (S0613)
A 100 96 106.7 106.7
B 100 91.3 95.7 91.3
C 100 97.9 111.5 119.8
D 100 83.1 57.7 90
E 100 74.7 100.6 64.4
F 100 65.6 71.1 70.3
Mean (SD) 100 *
(0)
84.8 *
(12.75)
90.6
(21.37)
84.4
(21.02)
An identical number of monocytes from 6 horses (A-F) were differentiated in
parallel and the resulting numbers of cells after three days counted. Results are
shown as percentages with the number of cells generated with HS set as 100%.
Using non-parametric paired Wilcoxon signed-rank test, only the comparison of
HS vs. A15-101 was statistically significant (p ≤ 0.05), as indicated by the asterisks
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cells for all serum conditions. Cell yield was significantly
lower with A15-101 serum in comparison to HS. To
assess differences in viability between the individual
serum conditions, immature eqMoDC were tested using
annexin V and propidium iodide staining and analysed
by flow cytometry for the presence of apoptotic and/or
dead cells. Figure 2 shows that cells cultured in the pres-
ence of any of the three FBS exhibited a significantly
higher percentage of dead cells than cells cultured with
HS. While differences between the individual FBS were
non-significant, the highest proportion of dead cells
could be observed in the cells incubated with the A15-
101 serum.
Surface marker expression of eqMoDC reflects maturation
status and is comparable between serum conditions
Differentiation and maturation of eqMoDC in vitro is
reflected by changes in the expression of surface
markers. To compare our findings with previous results
and established knowledge [17] CD14, CD86, and CD206
were selected for analysis by flow cytometry on eqMoDC
before and after maturation and for comparison of
eqMoDC generated under the different serum conditions.
While CD14 is a monocyte marker that should be mark-
edly down-regulated during the differentiation process
from monocytes to MoDC, CD206 is a particular marker
for immature MoDC to be down-regulated upon activa-
tion. CD86 was expected to be up-regulated during mat-
uration/activation of MoDC. As expected, no significant
difference could be observed in CD14 expression between
immature and mature eqMoDC under any serum condi-
tion (Fig. 3a). Interestingly, CD14 remained significantly
more highly expressed in immature eqMoDC obtained
under the influence of the FBS batches (S0113) or (S0613)
than in the presence of the A15-101 FBS batch. For CD86
expression, no significant difference between serum condi-
tions could be observed (Fig. 3b). Nonetheless, eqMoDC
incubated with the maturation cocktail showed an up-
regulation of CD86 under all serum conditions. This up-
regulation was statistically significant for FBS batches
a b
c d
Fig. 1 Morphology of eqMoDC at day 2 at 10× (large pictures) and 40× magnification (small inlaid pictures). Cells were incubated in the
presence of HS (a), FBS batch S0113 (b), FBS batch S0613 (c) and FBS batch A15-101 (d), respectively. Pictures are representative of cells from 6
tested horses. The arrow in (d) indicates giant cells, presumably after uptake of apoptotic material, only seen in the FBS A15-101 condition
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Fig. 2 Proportion of non-viable immature eqMoDC measured by flow
cytometry. The AF488 annexin V/Dead Cell Apoptosis Kit (Invitrogen)
was used for the analysis according to the protocol provided in
the kit. Each symbol indicates a separate horse (n = 6), with red
lines indicating the median value. A non-parametric paired sample
Wilcoxon (signed rank) test was used to determine significant
differences between HS and the respective FBS condition. P-values ≤
0.05 were considered statistically significant
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A15-101, S0113 and S0613. The difference in median
values between immature versus mature eqMoDC was
particularly low for HS. This was due to a considerable
expression of CD86 already on immature eqMoDC.
CD206 was clearly expressed upon differentiation of
immature eqMoDC under all culture conditions, albeit
at significantly lower levels in the presence of FBS A15-
101 (median, range. 65.2%, 55.1–79.6%) compared to
FBS batch S0113 (83.8%, 76.7–87.2%), or FBS batch
S0613 (84.5%, 73–89.6) and also to HS (82.1%, 76.6–
86.9%), although this difference was not statistically sig-
nificant. A significant down-regulation of CD206 upon
maturation could be observed in all four serum condi-
tions (Fig. 3c).
Transcriptome comparison of eqMoDC preparations and
populations
While the above results demonstrate that HS provided re-
sults similar to FBS for the differentiation of equine
eqMoDC, there is a considerable lack of antibodies in the
horse system to perform a more comprehensive analysis.
Aiming to test for hidden features, we resorted to gene ex-
pression profiling using equine-specific microarray ana-
lysis. Expression profiles of all three cell types were
analysed by 3D PCA, which demonstrated that while
monocytes (Mo), immature eqMoDC (iMoDC) and ma-
ture eqMoDC (mMoDC) are distinct populations, there
was no detectable effect of the serum conditions on the
gene expression profile of the different cell types (Fig. 4).
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Fig. 3 Surface marker expression of eqMoDC generated under the different serum conditions. EqMoDC were analysed by flow cytometry for cell
surface expression of CD14 (a), CD86 (b) or CD206 (c). Results are displayed as percentage of positive cells for the respective marker. EqMoDC
were generated under the respective serum conditions and were incubated overnight with the maturation cocktail (mature eqMoDC; dark grey
boxplots) or maintained as immature eqMoDC (light grey boxplots). A non-parametric paired sample Wilcoxon (signed rank) test was used to
identify significant differences between the HS condition and the different FBS conditions, respectively, within the maturation state (◊ indicates
differences between immature eqMoDC; □ indicates differences between mature eqMoDC). The same test was also applied to investigate signifi-
cant differences between immature and mature eqMoDC within each serum condition (indicated by asterisks). P-values ≤ 0.05 were considered
statistically significant
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Induction of T cell proliferation by antigen-primed MoDC
We analysed the eqMoDC generated under the different
serum conditions for their ability to induce proliferation
of T cells following antigen presentation. After the up-
take of either tetanus toxoid as recall antigen, or OVA as
a primary antigen, MoDC were incubated with autolo-
gous or heterologous (MLR) CD5+ T cells and prolifera-
tion of T cells was measured. While no proliferation
could be observed in T cells incubated with medium
only for the HS condition (median (range) 107 (67–170)
cpm), T cells incubated with FBS showed a notable back-
ground proliferation (median (range) 4384 (300–20667)
cpm with A15-101; 10709 (1935–36199) cpm with
S0113; 5385 (1049–57954) cpm with S0613, respectively)
(Fig. 5a). Similarly, non-specific proliferation of T cells
co-incubated with non-primed MoDC was significantly
higher in all FBS conditions (median (range) 15924
(5843–55404) cpm with A15-101; 12545 (5657–58043)
cpm with S0113; 17719 (14952–72847) cpm with S0613,
respectively) than in the HS condition (median (range)
6993 (2844–24414) cpm) (Fig. 5b). As expected, the
strongest induction of T cell proliferation was observed
with heterologous MoDC in the MLR control (Fig. 6a),
followed by autologous tetanus toxoid-primed MoDC as
a recall antigen presentation (Fig. 6b). T cell proliferation
was least pronounced when using the primary antigen
OVA (Fig. 6c). Serum culture conditions were compared
for each antigen condition. The gradation between MLR,
tetanus toxoid vs. OVA-elicited T cell responses was
most evident in the HS condition, with horses exhibiting
a median stimulation index for MLR of 5.14 (range
1.48–10.86) while for tetanus toxoid the SI was 2.75
(range 2.04–5.9). Three horses exhibited a stimulation
index > 2 for OVA (median = 1.84; range 1.5–2.79). Use
of HS in culture resulted in consistently higher stimula-
tion indices when compared to the FBS conditions for
MLR, tetanus and OVA, albeit not all differences were
statistically significant.
Discussion
Dendritic cells are key players in the immune system,
particularly competent in modulating the immune
Fig. 4 Gene expression analysis of equine monocytes (Mo) and
eqMoDC. Mo (dark blue), iMoDC (black, FBS batch S0113; yellow, HS)
and mMoDC (light blue, FBS batch S0113; pink, HS) were generated
in parallel from three horses each. Principal component analysis
(PCA) was carried out on the differentially expressed genes (1331
variables) and demonstrated that while the gene expression profiles
of the different MoDC stages are separate and different to Mo, the
genetic profile of the different sera cannot be further separated.
Three biological repeats (horses) were analyzed using Qlucore, one
dataset (iMoDC, HS) was discarded due to a technical issue in the
hybridization of the sub-arra C
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Fig. 5 Non-specific background proliferation induced by the different
serum conditions. T cell proliferation was measured by [3H] thymidine
incorporation assay after a 5 day incubation of either CD5+ T cells
alone (a) or co-incubation of CD5+ T cells with non antigen-primed
eqMoDC (b). Each symbol indicates a separate horse (n = 6), with red
lines indicating the median value. Non-parametric paired sample
Wilcoxon (signed rank) tests were used to compare HS with each FBS
and p-values ≤ 0.05 were considered statistically significant
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responses [1]. Thus they are promising tools both for can-
cer immunotherapy and to limit immune responses to
treat allergic reactions [30, 31]. The ability to generate
these otherwise scarce immune cells in large quantities
from progenitors and in particular monocytes, reinitiated
research in this field around 20 years ago [6, 7, 32]. The
identification of distinct DC populations in vivo, among
them DC specialized in cross-presenting antigens to CD8+
cytotoxic T cells [33] has widened the opportunities to
study specialized subsets of DC. MoDC remain the first
choice for personalized therapeutic approaches, such as
loading DC ex vivo, as they were shown to substitute for
all DC functions, including cross-presentation [34].
Fetal bovine serum (FBS) is widely used in cell culture
media, but has come under more intense scrutiny in re-
cent years: as well as being a possible source for disease
transmission its use in therapeutic vaccines may lead to
adverse immune reactions against FBS [35, 36]. The prob-
lem of batch variability, including the contamination with
LPS (which is detrimental to MoDC differentiation), was
immediately recognised as an issue for therapeutic use of
DC [37].
Early work to replace the 5–10% FBS commonly used
to generate human MoDC by an equal amount of hu-
man sera (either autologous or batch tested) has not
been successful (Steinbach et al., unpublished; various
personal communications). This was explained by the
plasticity of monocytes as uncommitted myeloid cells
during differentiation allowing them to acquire a macro-
phage rather than a DC phenotype [38]. It was accord-
ingly suggested to replace the 10% FBS by 1%
autologous plasma, but while the phenotypical and func-
tional data were analogous to FBS-derived MoDC, the
DC yield obtained was very low (around 20% compared
to FBS based protocols) with a significantly reduced en-
richment [9]. This was offset by larger scale production
[39], which, however, does not address the issue of cell
debris from dead cells in such cultures.
In horses, previous studies to generate MoDC under
the influence of GM-CSF and IL-4 used FBS [14, 16, 17]
and pilot studies have also shown the potential use of
such ex vivo generated MoDC for treatment of tumors
[40]. However, previous experience where FBS-specific
IgE was induced through MoDC application [36], elimi-
nated such equine MoDC for the purpose of allergen
immunotherapy.
In a preliminary experiment, we compared the use of
autologous and heterologous equine serum with FBS
from PAA (A15-101), which was used in one of our la-
boratories for the maintenance of cells lines. Intri-
guingly, while both equine serum preparation delivered
encouraging results, the A15-101 FBS led to morpho-
logically more heterogeneous populations with giant
cells that we presumed to be the result of cell death
followed by phagocytosis, not matching previous de-
scriptions [14, 17]. Since the results obtained with the
two serum preparations from horses were very similar,
we decided to generate a heterologous serum to achieve
a better standardisation for subsequent experiments. In
addition, it became necessary to expand our study to
other FBS batches able to reproduce previous results
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[17]. Thus, we decided to conduct a small study compar-
ing three different FBS with HS during the generation of
equine MoDC and their application in functional assays.
The aim was to determine if equine MoDC could be
successfully generated using horse serum that was
freshly prepared rather than commercial serum that pre-
viously failed to deliver equine MoDC (Steinbach et al.,
unpublished).
The differentiation from monocytes to MoDC is char-
acterised by the formation of tight cell clusters, where
cells gradually become non-adherent and develop typical
dendrites [6, 41]. It was notable that equine MoDC dif-
ferentiated with HS developed larger clusters faster than
monocytes incubated with FBS, which showed only lim-
ited clustering by day 2 (Fig. 1). It is not known whether
the formation of cell clusters and thus close cell-to-cell
contact is necessary for differentiating monocytes to be-
come fully functional, but eqMoDC cultured in the pres-
ence of HS were also significantly more viable. It is thus
likely that cell-cell signalling within clusters promotes
viability of cells in culture. Not surprisingly and in line
with the preliminary data, FBS batch A15-101 showed
the highest proportion of non-viable cells. These results,
however, do not explain whether HS contains additional
viability factors which are lacking in FBS, or whether the
changes and additions made to FBS batch A15-101 were
detrimental to eqMoDC differentiation. Interestingly,
there seems to be an inherent variation between individ-
ual horses in the proportion of non-viable cells that was
independent of the serum used. Regardless of the serum
condition, the same horse delivered the highest as well
as the lowest proportion of dead cells. Thus, it is reason-
able to propose that individual disposition (from genetics
to an individual’s current health status) likely affects the
generation of eqMoDC ex vivo. This resonates an earlier
study showing that monocytes from Lupus Erythemato-
sus patients required more GM-CSF and IL-4 to obtain
viable DC [42].
As with the morphology and viability, clear differences
were observed for the phenotype between the four tested
sera: again, eqMoDC incubated with the two FBS from
Biochrom displayed very similar phenotypes and matur-
ation patterns, which were likely due to a similar FBS
composition that should be observed using high per-
formance FBS batches. Slightly surprising though was
the relatively high level of CD14 remaining on MoDC
generated with the Biochrom FBS. Since we tested all
media for LPS this can be excluded as the causative fac-
tor. MoDC generated with HS expressed slightly higher
levels of CD86 already at the immature stage. Overall,
though all cells displayed a phenotype in accordance
with MoDC differentiation and maturation and only
trends were observed that made cells treated with HS
preferable, i.e. is more in line with the published gold
standard, to those treated with FBS. Accordingly, it was
not surprising that in a whole transcriptome analysis the
three differentiation stages were clearly separable, whereas
the different sera clustered strongly together similar to
previous results [17]. This is not astonishing, since across
a whole population of cells of the same lineage, only mi-
nute shifts in gene expression will suffice to induce the
changes in protein expression and morphology such as
observed by flow cytometry. This emphasises that all four
sera delivered equine MoDC of some quality.
It is important to consider that ultimately, DC are not
defined by the presence or absence of certain markers,
but by their functional ability to stimulate T cells. Here,
HS clearly demonstrated an advantage through not in-
ducing non-specific proliferation. This result, observed
with all batches of FBS, may reflect their xenogenous
and antigenetic nature, with T cells in adult horses react-
ing against foreign serum components or exogenous
agents. To exclude the latter we tested the FBS batches
for the presence of pestivirus RNA (a common contam-
inant of FBS) and can exclude this as a factor. However,
as all horses in this study were regularly vaccinated, a
sensitisation to foreign proteins present in these vaccines
may well have occurred and has been described for
equine vaccines before [43]. The strongest proliferation
was induced in the heterologous mixed leukocyte reac-
tion (MLR) followed by an antigen-specific recall re-
sponse against tetanus toxoid. This was to be expected
compared to a primary antigen like OVA, where the re-
sponse relies on the activation of naïve rather than
memory T cells. Using the stimulation index to deter-
mine the specific reaction above the background, the
best performance was observed with HS.
Conclusion
It can be concluded that eqMoDC generated in the pres-
ence of HS showed improved morphological characteris-
tics, higher cell viability and were superior with a more
robust performance in the functional T cell assays. While
HS did not perform significantly better in all assays, it is
the mixture of results that favours HS for the generation
of eqMoDC. While PAA’s FBS (A15-101) did not per-
form worst in all experiments, its inferior performance
in morphology and viability assays and the lack of clarity
surrounding its composition and thereby functional re-
producibility exclude this product completely from use
[19]. While FBS can in general be considered further for
in vitro research, the results here re-emphasize the need
for batch testing. These results are very encouraging for
the clinical application of equine MoDC and confirm a
most recent report using cells generated with horse
serum for recall responses [44]. However, the effect of
autologous serum or different serum conditions on the
phenotype and function of equine MoDC had not been
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systematically investigated previously. Prior to clinical
application, though horse sera need to be tested exten-
sively for extraneous agents, like the widespread equine
hepaciviruses and or treated for inactivation of such.
Thus, the serum free generation of MoDC would be de-
sirable, but this has proven inefficient, resulting in very
limited cell numbers [8, 45] and is still a matter of de-
bate [24–26, 46, 47]. With the recent progress in defin-
ing serum free media for various purposes (discussed in
[48]) this goal can be achieved in the near future, but re-
quires further studies to ensure good compliance with
MoDC functionality as well.
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